Akebia Therapeutics, Inc. Share Price

Akebia Therapeutics, Inc. Share Price

NASDAQ: AKBA | Micro Cap
$0.79
+$0.02 (2.58%) Last updated on 29 Oct, 2026 | 20:38 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Akebia Therapeutics, Inc. Stock Performance

Open
$0.77
Prev. Close
$0.77
Circuit Range
N/A
Day Range
$0.76 - $0.79
Year Range
$0.54 - $2.53
Volume
28,151
Average Traded
$0.78

Akebia Therapeutics, Inc. Share Price Today

As of 29 October 2026, Akebia Therapeutics, Inc.'s share price is $0.79. The stock opened at $0.77, compared to its previous close of $0.77. During today's trading session, Akebia Therapeutics, Inc.'s share price traded between $0.76 and $0.79, with an average price of $0.78. Over the past 52 weeks, the stock has recorded a high of $2.53 and a low of $0.54. In terms of performance, Akebia Therapeutics, Inc.'s share price has declined by 42.66% over the last six months and is down 63.98% on a year-on-year basis.

Akebia Therapeutics, Inc. Share Price Chart

Line chart of the Akebia Therapeutics, Inc. price trend over the selected period. The price rose overall, ranging from 0.76 to 0.79, ending at 0.79.
$0.76$0.79
L
Show Current Price
H

Akebia Therapeutics, Inc. Stock Fundamentals & Key Indicators

Market Cap
$204.23M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-0.11
Revenue (TTM)
$236.20B
Return On Equity (TTM)
-118.58%
Profit Margin
-2.27%
Debt to Equity
1.98
Quarterly Earnings Growth YoY
-1750.00%

Akebia Therapeutics, Inc. Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$58.77$57.62$53.54$49.13
Net Profit$0.54-$12.24-$9.05-$8.91
Net Profit Margin0.92%-21.24%-16.90%-18.14%
Income ChangeN/A-2366.67%26.06%1.55%

Akebia Therapeutics, Inc. Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$292.48$194.62$160.18$236.20
Net Profit-$94.23-$51.93-$69.41-$5.35
Net Profit Margin-32.22%-26.68%-43.33%-2.27%
Income ChangeN/A44.89%-33.66%92.29%

About Akebia Therapeutics, Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Akebia Therapeutics, Inc. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$0.91
$0.79
-13.79%
Sep 2026
$0.92
$0.92
-1.92%
Aug 2026
$1.32
$0.94
-29.13%
Jul 2026
$1.16
$1.32
+17.78%
Jun 2026
$1.02
$1.13
+9.76%
May 2026
$1.40
$1.02
-25.99%
Apr 2026
$1.41
$1.39
-0.36%
Mar 2026
$1.28
$1.39
+5.30%
Feb 2026
$1.39
$1.32
-6.38%
Jan 2026
$1.60
$1.41
-12.15%
Dec 2025
$1.59
$1.60
+1.58%
Nov 2025
$2.19
$1.58
-28.34%

AKBA Share Price FAQs